| Birth control (13) |  |
similar to those used for contraception. The material can accommodate different anti-HIV drugs and the team is testing several others for effectiveness.
I appreciate that controversy exists surrounding abortion. I would implore such people to consider the benefits which may arise as a consequence of experiments such as this.
UV sterilisation and so on-this is a promising one, because it's cheap, and it's a catchy idea that people can get hold of
UV sterilisation and so on-this is a promising one, because it's cheap, and it's a catchy idea that people can get hold of
placenta and embryonic tissue donated by women who had undergone abortions. The samples were stained using a dye to see where glycogen was present in the tissues from different stages of pregnancy.
He used his research to launch three biotech companies centered on forensic science, fertility assessment and contraception methods.
The difference is that Ovastasis plans to use those protein biomarkers as targets for a novel female birth control medication. he identification of drug targets that are selective to the egg
or to the sperm gives you opportunities to create small-molecule drugs for female and male contraception, contraceptive vaccines,
Currently approved female birth control medications work by manipulating the female body estrogen and progesterone levels. While effective, these drugs are steroids
Ovastasis is developing a new form of birth control that will interact only with a woman reproductive cells to arrest their development.
The same biomarkers that will help limit the area of impact for Ovastasis birth control will also help Neoantigenics confine the toxic effects of cancer treatment to growing egg and tumor cells.
They say their invention aligns with voluntary contraception programs supported by philanthropic global health organizations such the Bill and Melinda Gates Foundation.
The team at Strathclyde is based within the Robertson Trust Laboratory for Electronic Sterilisation Technologies (ROLEST)
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011